English

This graphic discusses the effects of the COVID-19 pandemic on the HIV response

This infographic discusses how girls and women make up more than half of the 37.7 million people living with HIV. Ending AIDS by 2030 requires that we address girls’ and women’s diverse roles by putting them at the centre of the response.

This infographic discusses how TB is the leading cause of death among people living with HIV.

This document discusses how NASTAD strongly encourages 340B program administrators to incorporate health equity into their programs. Health equity means that everyone has a fair and just opportunity to be as healthy as possible and this requires removing obstacles to health such as structural racism and the intentional lack of social safety nets and investments that lead to poverty, unstable housing, food deserts, inadequate infrastructure and environmental injustices. 

This document supports viral hepatitis program administrators in educating and preparing leadership to support 340B program implementation and partnerships. 

The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years.

The recent emergence of the Coronavirus Disease (COVID-19) calls for enhanced cooperation between public health authorities, homeless service systems, and other partners at the local level. HUD strongly encourages CoCs to contact their local public health departments, Healthcare for the Homeless agencies, and other local health partners to ensure the unique needs and opportunities related to the homeless service system are incorporated in plans to prevent and respond to infectious diseases like COVID-19.

This resource walks through some of the basic elements of the Medicare program and provides information to support RWHAP Part B/ADAP staff in adapting program activities to better coordinate with Medicare coverage, including providing premium and cost-sharing assistance for clients. For a more comprehensive overview of the Medicare program as well as client-facing resources, please visit the Medicare resources created as part of the Access, Care, & Engagement (ACE) Technical Assistance Center.

The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.

Although hepatitis B is preventable and treatable, there is still no cure for this disease. In addition to the devastating toll on patients and their families, ignoring hepatitis B costs the U.S. an estimated $4 billion per year in medical costs. Yet, the NIH will spend only $66 million in FY 2021 on hepatitis B research. Read more in this fact sheet.